Phase 1 trial reports high response rates with anito-cel CAR T therapy

A phase 1 study evaluated anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy with a novel d-domain binder, in 38 patients with heavily pretreated relapsed or refractory multiple myeloma. The trial reported a 100% overall response rate, with 79% achieving complete response, median progression-free survival of 30.2 months, and 36-month overall survival of 65%; severe cytokine release syndrome and neurotoxicity were rare. The authors also reported that in vitro comparisons showed the ddBCMA binder produced less cytokine release than a dual-VHH binder corresponding to ciltacabtagene autoleucel's published sequence, without off-target cytotoxic effects.

Most relevant for: Patients with relapsed or refractory multiple myeloma who have received three or more prior lines of therapy or have triple-class refractory disease.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.